Novavax Inc at Guggenheim Vaccines and Infectious Diseases Conference (Virtual) Transcript
Good afternoon, everybody, and thanks for joining us for our penultimate fireside chat session with -- and here today with Novavax. I'm Seamus Fernandez, the global [biotech] analyst here at Guggenheim. And I'm also joined by my biotech colleague, Evan Wang. He's our CoV-2 expert. We're also joined from the Novavax team here by Greg Glenn, President of R&D; and John Trizzino, Chief Business Officer and Chief Financial Officer.
Novavax is really one of the frontrunners in the development of COVID vaccines. The company has efficacy trials ongoing in the U.K. and South Africa, and plans to begin its 30,000 patient U.S. trial in the next month or so. The company has rapidly developed its vaccine and has received over $2 billion in funding from CEPI and OWS.
In flu, the company announced results from its Phase III trial in March and is preparing to submit its BLA. And with that, let me turn it over to the Novavax team who will provide a brief overview of the company and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
